Insulin degludec


Generic Medicine Info
Contraindications
Hypersensitivity. Hypoglycaemic episodes.
Special Precautions
Patient with infections, fever, diseases affecting the adrenal, pituitary and thyroid gland, and those at risk for hypokalaemia. Not intended for treatment of diabetic ketoacidosis. Hepatic and renal impairment. Children. Lactation. Patient Counselling Rotate injection sites within the same body region and use a new needle for each injection. This drug may cause hypoglycaemia which may impair ability to concentrate or react, if affected, do not drive or operate machinery. Monitoring Parameters Closely monitor plasma glucose levels (especially during transfer from other insulin product); HbA1c (at least twice yearly), electrolytes, lipid profile, renal and hepatic function, weight. Assess for signs of hypoglycaemia.
Adverse Reactions
Significant: Lipodystrophy, hypoglycaemia, hypokalaemia, formation of insulin antibodies. Gastrointestinal disorders: Gastroenteritis, diarrhoea. General disorders and administration site conditions: Inj site reactions (e.g. haematoma, swelling, erythema), peripheral oedema. Immune system disorders: Urticaria. Investigations: Weight gain. Nervous system disorders: Headache. Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, upper respiratory infection, sinusitis.
Potentially Fatal: Severe hypoglycaemia, severe allergic reactions, including anaphylaxis.
Drug Interactions
Risk of fluid retention and CHF when given with peroxisome proliferator-activated receptor (PPAR)-γ agonists (e.g. pioglitazone). Increased risk of hypoglycaemia with oral antidiabetic agents, glucagon-like peptide-1 (GLP-1) receptor agonists, ACE inhibitors, MAOIs, salicylates, sodium-glucose cotransporter 2 (SGLT2) inhibitors, sulfonamides, and anabolic steroids. Decreased glucose lowering effect with oral contraceptives, glucocorticoids, thiazides, thyroid hormones, growth hormone, sympathomimetics, glucagon, niacin, protease inhibitors, danazol. Somatostatin analogues (e.g. octreotide, lanreotide) may either increase or decrease insulin requirement. Beta-blockers, clonidine, guanethidine, lithium and reserpine may mask the symptoms of hypoglycaemia.
ATC Classification
A10AE06 - insulin degludec ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.
Disclaimer: This information is independently developed by CIMS based on insulin degludec from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in